Sinopharm reports medical-device revenue. CICC sets RMB 38.0 target for Sinopharm stock

Published on 10/25/2026 at 01:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nine-month revenue fell 0.11 percent to RMB 55.07 billion year over year. CICC kept an Outperform rating for Sinopharm stock on October 21, 2026.

Medical device data and profit

Sinopharm Medical Device reported RMB 55.3 billion in revenue for the nine months ended September 30, 2026.
Third-quarter revenue reached RMB 18.80 billion, while net profit was RMB 346.29 million on October 20, 2026.
Sinopharm stock had a market capitalization of HKD 47.9 billion as of October 23, 2026.

Sinopharm, CNE100000FN7, Illustration mit AI erstellt.

Sinopharm Group (ISIN CNE100000FN7) disclosed RMB 55.3 billion in revenue from its medical-device subsidiary for the nine months ended September 30, 2026, according to Futunn on October 22, 2026. The disclosure combined modest revenue growth with pressure on operating profit, making profitability and cash flow the key investor questions.

Medical device revenue grew

The subsidiary's revenue increased 1.04 percent year over year to RMB 55.3 billion. Operating profit fell 11.07 percent to RMB 856 million, while comprehensive income attributable to parent-company owners declined 1.03 percent to RMB 391 million, according to Futunn.

Operating cash flow was negative RMB 1.72 billion for the period, compared with negative RMB 4.13 billion a year earlier. The 58.33 percent improvement reduces the cash drain, but the negative balance keeps working-capital execution central to the investment case.

Three results milestones

On October 20, 2026, Sinopharm Group reported third-quarter revenue of CNY 18,799.73 million and net profit of CNY 346.29 million, versus CNY 18,327.89 million and CNY 291.21 million a year earlier, according to Zonebourse. On October 21, 2026, CICC said the first nine months were in line with expectations and maintained an Outperform rating with a CNY 38.0 target, according to Futunn.

On October 22, 2026, the medical-device disclosure added a second operating signal: revenue expanded while operating profit contracted. That mix suggests that cost control, product mix and procurement pressure matter more than sales growth alone.

What does the target mean?

CICC's CNY 38.0 target was paired with 2026 and 2027 net profit forecasts of CNY 2.173 billion and CNY 2.374 billion. The same assessment identified price pressure from volume-based procurement and slower expansion of new business lines as risks, keeping the target dependent on improving profitability.

Stock stays tied to execution

Sinopharm Group was last at HKD 15.34 on the Hong Kong Stock Exchange on October 23, 2026 at 4:08 p.m. HKT. Its market capitalization was HKD 47.9 billion, and its 52-week range was HKD 14.55 to HKD 22.34 as of that date. The further course of trading is shown by the continuously updated real-time quote of Sinopharm stock.